Windlas Biotech Ltd. AI Stock Analysis
Want to see IN:WINDLAS full AI Analyst Report?
Windlas Biotech Ltd. (WINDLAS) AI Stock Analysis
Windlas Biotech Ltd.
(NSE:WINDLAS)
Windlas Biotech scores moderately above average, driven primarily by a strong growth record and an exceptionally clean, low-debt balance sheet that gives it flexibility to fund expansion. The main drags are a sharply projected gross margin decline in FY2026 estimates and highly volatile free cash flow generation, which together raise questions about earnings quality and margin sustainability. Technically, the stock remains in a longer-term uptrend above its 100- and 200-day averages, though a negative MACD and a slip below the 50-day average signal a short-term consolidation. Valuation at ~31x earnings with a modest 0.63% yield prices in continued growth, leaving limited room for execution missteps. Earnings call and corporate event data were unavailable and excluded, with their weight redistributed across the remaining components.
Windlas Biotech Ltd. (WINDLAS) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 20.61B
- Dividend Yield
- 0.64%
- Average Volume (3M)
- 6,337
- Price to Earnings (P/E)
- 30.9
- Beta (1Y)
- 0.96
- Revenue Growth
- 18.48%
- EPS Growth
- -0.41%
- Country
- India
- Employees
- 1,385
- Sector
- General
- Sector Strength
- 55
- Industry
- Drug Manufacturers - Specialty & Generic
Windlas Biotech Ltd. Business Overview & Revenue Model
Company Description
Windlas Biotech Limited functions as a comprehensive contract development and manufacturing organization (CDMO). Its CDMO offerings span the full product lifecycle, encompassing initial discovery, subsequent development, licensing, and large-scale co...
Windlas Biotech Ltd. Financial Statement Overview
Summary
Revenue has nearly doubled over five years (₹4.27B in FY2021 to ₹7.60B in FY2025, with ₹9.04B projected for FY2026) and net income has grown from ₹158M to ₹610M, earning a solid Income Statement score of 68. The balance sheet is the standout strength (score 78), with near-zero leverage (D/E of 0.008–0.064), steadily compounding equity to ₹5.06B, and total assets expanding to ₹7.60B — rare financial discipline in capital-intensive pharma manufacturing. Offsetting this, cash flow is the weak link (score 55): free cash flow has swung from negative in FY2022–FY2023 to ₹713M in FY2024 before collapsing to ₹160M in FY2025, pointing to lumpy capex and heavy working capital swings and unreliable cash conversion. The projected gross margin compression from ~38% to ~18% and EBITDA margin slide to ~11.6% in FY2026 estimates is a material concern that caps the score.
Income Statement
68PositiveBalance Sheet
78PositiveCash Flow
55Neutral| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.84B | 9.04B | 7.60B | 6.29B | 5.11B | 4.63B |
| Gross Profit | 1.72B | 1.64B | 2.88B | 2.28B | 1.81B | 1.61B |
| EBITDA | 1.15B | 1.05B | 1.12B | 916.40M | 701.91M | 591.29M |
| Net Income | 666.97M | 664.56M | 609.94M | 581.87M | 426.26M | 380.89M |
Balance Sheet | ||||||
| Total Assets | 10.15B | 9.07B | 7.60B | 6.26B | 5.29B | 4.91B |
| Cash, Cash Equivalents and Short-Term Investments | 2.62B | 2.70B | 2.40B | 2.04B | 1.32B | 1.76B |
| Total Debt | 534.29M | 352.42M | 325.97M | 36.41M | 49.93M | 66.37M |
| Total Liabilities | 4.46B | 3.27B | 2.55B | 1.76B | 1.27B | 962.33M |
| Stockholders Equity | 5.69B | 5.81B | 5.06B | 4.50B | 4.02B | 3.95B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 337.68M | 159.93M | 712.76M | -99.25M | -56.74M |
| Operating Cash Flow | 0 | 1.01B | 681.87M | 1.09B | 609.65M | 91.30M |
| Investing Cash Flow | 0 | -931.15M | -740.64M | -920.68M | -141.10M | -1.55B |
| Financing Cash Flow | 0 | -82.06M | 10.13M | -152.90M | -437.39M | 1.30B |
Windlas Biotech Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:WINDLAS, the sentiment is Positive. The current price of 988.60 is above the 20-day moving average (MA) of 927.69, below the 50-day MA of 1009.11, and above the 200-day MA of 873.90, indicating a neutral trend. The MACD of 6.06 indicates Negative momentum. The RSI at 56.22 is Neutral, neither overbought nor oversold. The STOCH value of 66.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:WINDLAS.
Windlas Biotech Ltd. Peers Comparison
Overall Rating
IN:SYNCOMF79Outperform
IN:VENUSREM72Outperform
IN:WINDLAS63Neutral
IN:MOREPENLAB55Neutral
IN:INDSWFTLAB51Neutral
IN:INDOCO48Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 79Outperform | INR 20.74B | 24.26 | ― | 0.45% | 0.44% | 48.60% | |
| 72Outperform | INR 19.37B | 15.98 | ― | 0.69% | 20.22% | 73.03% | |
| 63Neutral | INR 20.40B | 30.89 | ― | 0.64% | 18.48% | -0.41% | |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| 55Neutral | INR 50.55B | 26.93 | ― | 0.22% | 30.20% | 91.17% | |
| 51Neutral | INR 29.21B | 34.50 | ― | ― | 66.39% | -72.31% | |
| 48Neutral | INR 22.26B | 71.18 | ― | 0.08% | 10.75% | ― |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:WINDLAS | Windlas Biotech Ltd. | 988.60 | 188.94 | 23.63% | |
| IN:INDOCO | Indoco Remedies Limited | 241.15 | -10.18 | -4.05% | |
| IN:INDSWFTLAB | Ind-Swift Laboratories Ltd. | 335.90 | 240.50 | 252.10% | |
| IN:MOREPENLAB | Morepen Laboratories Limited | 92.25 | 47.33 | 105.34% | |
| IN:SYNCOMF | Syncom Formulation (India) Ltd. | 22.06 | 6.15 | 38.65% | |
| IN:VENUSREM | Venus Remedies Limited | 1449.30 | 762.87 | 111.14% |
Windlas Biotech Ltd. Corporate Events
Windlas Biotech Schedules Earnings Call for Q2 and H1 FY27 Results
Windlas Biotech Limited operates in the pharmaceutical and biotechnology sector, producing healthcare and biopharmaceutical products for the Indian market and beyond. The company is publicly listed on BSE and NSE, signaling its integration into India...
Windlas Biotech Files Q1 FY27 Earnings Call Transcript With Indian Exchanges
Windlas Biotech Limited has released the transcript of its Q1 FY27 earnings conference call, formally submitting the document to the listing and compliance departments of BSE and the National Stock Exchange of India in line with SEBI disclosure regul...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026
